시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 저프로트롬빈혈증 치료 시장 보고서(2025년)
Hypoprothrombinemia Treatment Global Market Report 2025
상품코드 : 1769619
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,312,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,124,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,936,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

저프로트롬빈혈증 치료 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2029년에는 CAGR 8.7%로 성장할 전망이며, 21억 2,000만 달러로 성장이 예측됩니다. 예측 기간에 예상되는 성장은 출혈성 질환의 유병률 증가, 재택 치료에 대한 수요 증가, 헬스케어 인프라 확대, 전문 클리닉 및 혈액학에 특화된 케어 센터의 성장, 개별화 의료의 채택 증가에 기인하고 있습니다. 이 기간 주요 동향에는 유전자 재조합 응고 인자, 개별화 의료 및 유전자 프로파일링, 혁신적 약물 전달 시스템, 포인트 오브 케어 진단 기술, 인공지능(AI)과 데이터 분석 통합 등의 진보가 포함됩니다.

출혈성 질환의 유병률 상승은 저프로트롬빈혈증 치료 시장의 성장을 가속할 것으로 예측됩니다. 출혈성 질환은 혈액이 제대로 응고되지 않아 과다한 출혈이나 장기 출혈을 일으키는 질환입니다. 이러한 유병률의 증가는 진단 방법의 개선과 인지도의 향상에 기인한 바가 크며, 그러한 상태의 보다 정확한 특정과 보고로 이어지고 있습니다. 저프로트롬빈혈증 치료는 부족한 프로트롬빈 농도를 보충함으로써 환자의 혈액 응고 능력을 회복시키는 것입니다. 예를 들어 영국 학술지 BMC Health Services Research에 따르면 영국에서는 2022년 4월부터 2023년 3월까지 남성 5,032명(18세 이상), 총 6,662명이 혈우병 A로 진단됐으며 이 중 2,421명이 인자보충요법 또는 에미시주맙에 의한 치료를 받았습니다. 같은 기간 성인 1,022명을 포함한 남성 1,342명이 혈우병 B로 기록됐고, 그 중 479명이 인자보충요법을 받았습니다. 따라서 출혈성 질환의 유병률 증가는 저프로트롬빈혈증 치료 시장의 확대를 촉진할 것으로 예상됩니다.

바이오시밀러의 채용 확대가 저프로트롬빈혈증 치료 시장의 향후 성장을 가속할 것으로 예측됩니다. 바이오시밀러란 이미 승인된 오리지널 생물학적 제제와 유사성이 높고 안전성이나 유효성에 큰 차이가 없는 생물학적 제제를 말합니다. 바이오시밀러 의약품의 이용이 확대되고 있는 배경에는, 선발품의 생물학적 제제와 동등한 안전성과 유효성을 유지하면서, 보다 저렴하고 이용하기 쉬운 치료의 선택지를 제공할 수 있는 가능성이 있다는 것에 있습니다. 저프로트롬빈혈증 치료에서 바이오시밀러 제제는 선발품 응고인자 제제를 대체할 수 있는 비용 대비 효과가 높은 대체 요법을 제공하여 중요한 응고 관리에 대한 환자의 접근성을 향상시킵니다. 예를 들어 혁신적인 주요 바이오의약품 기업을 대표하는 미국 업계 단체인 PhRMA에 따르면 2022년 말까지 40개의 바이오시밀러가 승인을 획득했고, 그 중 27개가 미국에서 판매되고 있습니다. 이처럼 바이오시밀러 이용 확대가 저프로트롬빈혈증 치료 시장 확대를 견인하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향 및 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁 및 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석 및 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도 및 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹 및 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문 및 전략

제36장 부록

AJY
영문 목차

영문목차

Hypoprothrombinemia treatment involves medical approaches designed to restore sufficient levels of prothrombin (Factor II), a crucial protein in blood clotting. The goal is to prevent or manage abnormal bleeding by addressing the underlying cause, which may include genetic factors, vitamin K deficiency, liver disease, or excessive use of anticoagulants.

The primary treatment types for hypoprothrombinemia are Type I and Type II deficiency treatments. Type I hypoprothrombinemia (true prothrombin deficiency) is commonly managed with prothrombin complex concentrates (PCCs) or fresh frozen plasma (FFP) to replenish prothrombin levels and enhance clotting function. Treatment options include vitamin K, fresh frozen plasma, prothrombin complex concentrates, and recombinant prothrombin. These therapies are used for conditions such as vitamin K deficiency, liver diseases like cirrhosis and hepatitis, anticoagulant-related hypoprothrombinemia, genetic disorders, and malabsorption syndromes. Drug administration routes include oral, injectable, intravenous, intramuscular, and transfusion-based methods. The main end users are hospitals, specialty clinics, and homecare providers.

The hypoprothrombinemia treatment market research report is one of a series of new reports from The Business Research Company that provides hypoprothrombinemia treatment market statistics, including the hypoprothrombinemia treatment industry global market size, regional shares, competitors with the hypoprothrombinemia treatment market share, detailed hypoprothrombinemia treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the hypoprothrombinemia treatment industry. This hypoprothrombinemia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The hypoprothrombinemia treatment market size has grown strongly in recent years. It will grow from $1.39 billion in 2024 to $1.52 billion in 2025 at a compound annual growth rate (CAGR) of 9.0%. The growth during the historic period can be attributed to the increasing prevalence of liver diseases, a rising incidence of malabsorption syndromes, heightened attention to coagulation disorders in critical care, greater awareness of bleeding disorders, and a surge in vitamin K deficiency cases.

The hypoprothrombinemia treatment market size is expected to see strong growth in the next few years. It will grow to $2.12 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%. The growth projected for the forecast period can be attributed to the increasing prevalence of bleeding disorders, rising demand for home care treatments, expansion of healthcare infrastructure, growth in specialty clinics and hematology-focused care centers, and the increasing adoption of personalized medicine. Key trends during this period include advancements in recombinant coagulation factors, personalized medicine and genetic profiling, innovative drug delivery systems, point-of-care diagnostic technologies, as well as the integration of artificial intelligence (AI) and data analytics.

The rising prevalence of bleeding disorders is expected to drive growth in the hypoprothrombinemia treatment market. Bleeding disorders are conditions where blood does not clot properly, causing excessive or prolonged bleeding. This increase in prevalence is largely due to improved diagnostic methods and greater awareness, leading to more accurate identification and reporting of such conditions. Hypoprothrombinemia treatments help restore clotting ability in patients by replenishing deficient prothrombin levels. For example, between April 2022 and March 2023 in the United Kingdom, a total of 6,662 males were diagnosed with hemophilia A, with 5,032 adults (aged 18 and above), and 2,421 of these patients received treatment through either factor replacement therapy or emicizumab, according to BMC Health Services Research, a UK-based journal. During the same period, 1,342 males were recorded with hemophilia B, including 1,022 adults, of whom 479 underwent factor replacement treatment. Therefore, the growing prevalence of bleeding disorders is anticipated to fuel the expansion of the hypoprothrombinemia treatment market.

The increasing adoption of biosimilars is expected to propel growth in the hypoprothrombinemia treatment market moving forward. Biosimilars are biologic medical products that are highly similar to an already approved original biologic, with no significant differences in safety or effectiveness. Their rising use is fueled by the potential to offer more affordable and accessible treatment options while maintaining comparable safety and efficacy to original biologics. In hypoprothrombinemia treatment, biosimilars provide cost-effective alternatives to original clotting factor therapies, enhancing patient access to vital coagulation management. For example, according to PhRMA, a US-based trade association representing leading innovative biopharmaceutical companies, by the end of 2022, 40 biosimilars had received approval, with 27 of them available in the United States. Thus, the growing use of biosimilars is driving the expansion of the hypoprothrombinemia treatment market.

Leading companies in the hypoprothrombinemia treatment market are concentrating on innovative therapies like non-activated four-factor prothrombin complex concentrate (4F-PCC) to quickly restore clotting factor levels and minimize bleeding risks in patients needing urgent anticoagulation reversal. The non-activated 4F-PCC is a plasma-derived treatment that includes clotting factors II, VII, IX, and X, used to promptly counteract the effects of vitamin K antagonists and manage bleeding disorders such as hypoprothrombinemia. For example, in January 2024, Octapharma USA, a subsidiary of Octapharma AG based in the US, launched Balfaxar, a non-activated 4F-PCC recently approved by the FDA for urgent reversal of vitamin K antagonist-induced coagulation deficiencies in adults undergoing emergency surgery or invasive procedures. This therapy contains essential vitamin K-dependent clotting factors along with antithrombotic proteins, fulfilling critical needs in hypoprothrombinemia treatment.

Major players in the hypoprothrombinemia treatment market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc, Sanofi S.A., AstraZeneca, Abbott, GlaxoSmithKline, Takeda Pharmaceuticals, Novo Nordisk A/S, Teva Pharmaceuticals, CSL Limited, Baxter International Inc., Fresenius Kabi AG, Grifols S.A., Sun Pharmaceutical Industries Ltd., Octapharma AG, Dr. Reddy's Laboratories, Pharmascience Inc., Amphastar Pharmaceuticals Inc., Pharma Cure Laboratories.

North America was the largest region in the hypoprothrombinemia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hypoprothrombinemia treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the hypoprothrombinemia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hypoprothrombinemia treatment market consists of revenues earned by entities by providing services such as diagnostic testing, hospital care, specialized transfusion services, therapeutic drug monitoring, and patient management programs. The market value includes the value of related goods sold by the service provider or included within the service offering. The hypoprothrombinemia treatment market also includes sales of plasma-derived concentrates, synthetic clotting factors, oral anticoagulant reversal agents, blood products, and plasma derivatives. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hypoprothrombinemia Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hypoprothrombinemia treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for hypoprothrombinemia treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hypoprothrombinemia treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Hypoprothrombinemia Treatment Market Characteristics

3. Hypoprothrombinemia Treatment Market Trends And Strategies

4. Hypoprothrombinemia Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Hypoprothrombinemia Treatment Growth Analysis And Strategic Analysis Framework

6. Hypoprothrombinemia Treatment Market Segmentation

7. Hypoprothrombinemia Treatment Market Regional And Country Analysis

8. Asia-Pacific Hypoprothrombinemia Treatment Market

9. China Hypoprothrombinemia Treatment Market

10. India Hypoprothrombinemia Treatment Market

11. Japan Hypoprothrombinemia Treatment Market

12. Australia Hypoprothrombinemia Treatment Market

13. Indonesia Hypoprothrombinemia Treatment Market

14. South Korea Hypoprothrombinemia Treatment Market

15. Western Europe Hypoprothrombinemia Treatment Market

16. UK Hypoprothrombinemia Treatment Market

17. Germany Hypoprothrombinemia Treatment Market

18. France Hypoprothrombinemia Treatment Market

19. Italy Hypoprothrombinemia Treatment Market

20. Spain Hypoprothrombinemia Treatment Market

21. Eastern Europe Hypoprothrombinemia Treatment Market

22. Russia Hypoprothrombinemia Treatment Market

23. North America Hypoprothrombinemia Treatment Market

24. USA Hypoprothrombinemia Treatment Market

25. Canada Hypoprothrombinemia Treatment Market

26. South America Hypoprothrombinemia Treatment Market

27. Brazil Hypoprothrombinemia Treatment Market

28. Middle East Hypoprothrombinemia Treatment Market

29. Africa Hypoprothrombinemia Treatment Market

30. Hypoprothrombinemia Treatment Market Competitive Landscape And Company Profiles

31. Hypoprothrombinemia Treatment Market Other Major And Innovative Companies

32. Global Hypoprothrombinemia Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hypoprothrombinemia Treatment Market

34. Recent Developments In The Hypoprothrombinemia Treatment Market

35. Hypoprothrombinemia Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기